Regulation of Platelet Function in Older Patients With Atrial Fibrillation

The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation. The main question it aims to answer is:

-Is platelet reactivity effectively controlled in patients over the age of 80 diagnosed with atrial fibrillation following the Watchman procedure.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Embolism and Thrombosis Heart Diseases Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms Thrombosis Thrombotic Risk Vascular Diseases

Age range

80 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Cardiovascular disease remains the leading cause of death and the risk for morbidity and mortality due to cardiovascular disease is thought to increases with age. Platelets play a key role in cardiovascular disease as their activation is essential for the formation of an arterial thrombus, the precursor to myocardial infarction and stroke. Additionally, thrombosis has been shown to be linked to cardiac pathologies including atrial fibrillation. The link between optimal prevention of thrombosis and limiting the risk associated with increased bleeding has not been fully elucidated. Hence, our understanding of the prothrombotic state of the platelet and thrombotic risk in people over the age of 80 is not well understood. In this study, we evaluate the prothrombotic state of the platelets in patients in the cardiovascular clinic over the age of 80 diagnosed with atrial fibrillation who are taking antiplatelet medications to determine the benefits of these interventions in prevention of thrombotic events, propagation of the risk for atrial fibrillation, and bleeding

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

diagnosed with atrial fibrillation, scheduled for a Watchman Procedure

Exclusion criteria

Healthy, taking antiplatelet medication

Treatment and study plan

Primary outcomes

Platelet reactivity

Time frame: blood draw will occur prior to Watchman procedure and antiplatelet administration and 90 days following Watchman procedure while patients are taking antiplatelet drugs

platelet reactivity will be measured before and after antiplatelet treatment in patients over 80. Outcomes will include 1) platelet aggregation, 2) integrin activation, 3) alpha and dense granule secretion, 4) T-TAS activation, and 5) TEG.

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Holinstat, PhD

CONTACT

[email protected]

734-764-4046

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2028
Study completion: 2028
First posted: Jul 24, 2026
Registry last updated: Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed